<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969329</url>
  </required_header>
  <id_info>
    <org_study_id>20170724</org_study_id>
    <nct_id>NCT03969329</nct_id>
  </id_info>
  <brief_title>A Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis</brief_title>
  <official_title>Phase 3, Single-arm, Open-label, Multidose, Titration, PK, PD, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to &lt; 18 Years of Age With Secondary HPT and Chronic Kidney Disease Receiving Maintenance Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide
      in the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects between ≥ 2 to
      &lt; 18 years of age, with chronic kidney disease (CKD) on hemodialysis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">June 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects will remain on treatment for 26 weeks from day 1 or until the time of renal transplant or parathyroidectomy, whichever occurs first. Subjects will receive a starting dose of etelcalcetide 0.07 mg/kg or 5 mg, whichever is lower, 3 times a week (TIW) intravenously. The dose of etelcalcetide will be titrated every 4 weeks (weeks 5, 9, 13, and 17) based on intact parathyroid hormone (iPTH), calcium, and safety to a maximum dose of 0.21 mg/kg or 15 mg, whichever is lower. The lowest protocol specified dose (PSD) for this study is 0.035 mg/kg or 2.5 mg, whichever is lower.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in intact parathyroid hormone (iPTH) from baseline during the efficacy assessment period (EAP) at weeks 20 to 26</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To evaluate the efficacy of etelcalcetide in reducing the intact parathyroid hormone (iPTH) level in children ages equal to or greater than 2 to less than 18 years with secondary hyperparathyroidism (SHPT) receiving maintenance hemodialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of a greater than 30% reduction from baseline in mean intact parathyroid hormone (iPTH) during the efficacy assessment period (EAP)</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To evaluate the efficacy of etelcalcetide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in corrected total serum calcium (Ca) and serum phosphorus from baseline during the EAP</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize change in laboratory markers of chronic kidney disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving corrected serum calcium (Ca) levels less than 8.0 mg/dL (2.0 mmol/L) at any time during the study</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize the safety of etelcalcetide treatment based on laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with changes in laboratory parameters, including clinical chemistry</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize the safety of etelcalcetide treatment based on laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with hypocalcemia (corrected serum calcium levels less than 8.4 mg/dL)</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize the safety of etelcalcetide treatment based on laboratory values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etelcalcetide plasma concentrations before and at the end of dialysis after single and multiple doses</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>Etelcalcetide plasma concentrations before and at the end of dialysis after single and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etelcalcetide PK parameter of maximum-observed concentration (Cmax)</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>Etelcalcetide plasma concentrations before and at the end of dialysis after single and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Etelcalcetide pharmacokinetic (PK) parameter of plasma trough concentrations (Cmin)</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize the pharmacokinetic (PK) of etelcalcetide treatment after single and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of all treatment-emergent adverse events</measure>
    <time_frame>20 to 26 weeks</time_frame>
    <description>To characterize the safety of etelcalcetide treatment based on adverse events. Nature, frequency, severity, and relationship to treatment of all adverse events, including those of special interest reported during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive etelcalcetide in addition to standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe</description>
    <arm_group_label>Etelcalcetide</arm_group_label>
    <other_name>Parsabiv - brand name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's legally acceptable representative has provided informed consent when the
             subject is legally too young to provide informed consent and the subject has provided
             written assent based on local regulations and/or guidelines prior to any
             study-specific activities/procedures being initiated.

          -  Male or female subjects greater than or equal to 2 to less than 18 years of age at the
             time of enrollment.

          -  Dry weight greater than or equal to 7 kg at the time of screening Week -1.

          -  Diagnosed with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT)
             undergoing hemodialysis/hemodiafiltration three times per week (TIW) at the time of
             screening greater than or equal to 1 month.

          -  Diagnosis of secondary hyperparathyroidism (SHPT) with the mean of the 2 consecutive
             central laboratory intact parathyroid hormone (iPTH) values greater than 300 pg/mL
             during screening, on separate days and within 2 weeks of enrollment obtained from the
             central laboratory during screening.

          -  Serum corrected calcium (cCa) value greater than or equal to 9.0 mg/dL obtained from
             the central laboratory during screening.

          -  Dialysate calcium (Ca) level greater than or equal to 2.5 mEq/L for at least 1 month
             prior to screening and throughout the duration of the study.

          -  Subject receiving active vitamin D sterols must have had no more than a maximum dose
             change of 50% within the 2 weeks prior to screening laboratory assessments, remain
             stable through enrollment, and be expected to maintain stable doses for the duration
             of the study, except for adjustments allowed per protocol.

          -  Subject receiving phosphate binders must have had no more than a maximum dose change
             of 50% within the 2 weeks prior to screening laboratory assessments, remain stable
             through enrollment, and be expected to maintain stable dose for the duration of the
             study, except for adjustments allowed per protocol.

          -  Subject receiving calcium (Ca) supplements must have had no more than a maximum dose
             change of 50% within the 2 weeks prior to screening laboratory assessments, remain
             stable through enrollment, and be expected to maintain stable dose for the duration of
             the study, except for adjustments allowed per protocol.

          -  Secondary hyperparathyroidism (SHPT) not due to vitamin D deficiency, per investigator
             assessment.

        Exclusion Criteria:

          -  Disease Related:

          -  History of congenital long QT syndrome, second or third degree heart block,
             ventricular tachyarrhythmia's, history of symptomatic ventricular dysrhythmias
             Torsades de Pointes or other conditions associated with prolonged QT interval.

          -  Anticipated or scheduled parathyroidectomy during the study period.

          -  Anticipated or scheduled kidney transplant during the study period.

          -  Subject has received a parathyroidectomy within 6 months prior to enrollment.

          -  Other Medical Conditions:

          -  Current malignancy or history of other malignancy, except non-melanoma skin cancers
             within the last 5 years.

          -  Prior/Concomitant Therapy:

          -  Use of concomitant medications that may prolong the QTc (eg, ondansetron, albuterol,
             sotalol, amiodarone, erythromycin, or clarithromycin). Refer to CredibleMeds.org for
             guidance.

          -  Receipt of cinacalcet therapy within 30 days prior to screening and through
             enrollment.

          -  Any previous use of etelcalcetide prior to screening and through enrollment.

          -  All herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by the
             subject within the 30 days prior to enrollment, and continuing use if applicable, will
             be reviewed by the Principal Investigator and the Amgen Medical Monitor. Written
             documentation of the review and Amgen acknowledgment is required for subject
             participation.

          -  Use of any over-the-counter or prescription medications within the 14 days or 5
             half-lives (whichever is longer) prior to enrollment that are not established
             therapies for subjects with renal disease or other conditions secondary to renal
             disease will be reviewed by the Principal Investigator and the Amgen Medical Monitor.
             Written documentation of the review and Amgen acknowledgment is required for subject
             participation. Paracetamol (up to 2 g per day) for analgesia will be allowed.

          -  Prior/Concurrent Clinical Study Experience:

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 30 days since ending treatment on another investigational device or drug
             study(ies). Other investigational procedures while participating in this study are
             excluded.

          -  Diagnostic Assessments During Screening:

          -  Subject has significant abnormalities on the most recent central laboratory test
             during the screening period prior to enrollment per the Investigator including but not
             limited to the following: a. Serum transaminase (alanine aminotransferase [ALT] or
             serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST], or serum
             glutamic oxaloacetic transaminase [SGOT]) greater than 1.5 times the upper limit of
             normal (ULN).

          -  Corrected QT interval greater than 500 ms, using Bazett's formula.

          -  Corrected QT interval greater than or equal to 450 to less than or equal to 500 ms,
             using Bazett's formula, unless written permission to enroll is provided by the
             investigator after consultation with a pediatric cardiologist.

          -  Subject has a clinically significant electrocardiogram (ECG) abnormality (eg, unstable
             arrhythmia) during screening that, in the opinion of the investigator, could pose a
             risk to subject safety or interfere with the study evaluation.

          -  Within the 3 Months Prior to Screening:

          -  New onset or worsening of a pre-existing seizure disorder.

          -  Subjects on anti-convulsant medication must be on a stable and therapeutic dose for 3
             months prior to screening (if blood level monitoring is clinically available, then the
             subject must have a therapeutic blood level within 1 week of enrollment).

        Other Exclusions:

          -  Female subject is pregnant or breastfeeding or planning to become pregnant or
             breastfeed during treatment and for an additional 3 months after the last dose of
             etelcalcetide. (Females of childbearing potential should only be included in the study
             after a confirmed menstrual period and a negative serum pregnancy test within 7 days
             prior to the first dose of investigational product).

          -  Female subjects of childbearing potential unwilling to use 1 acceptable method of
             effective contraception during treatment and for an additional 3 months after the last
             dose of investigational product. Refer to Appendix 5 for additional contraceptive
             information.

          -  Female subjects of childbearing potential with a positive pregnancy test assessed at
             screening by a serum pregnancy test.

          -  Subject has known sensitivity to etelcalcetide or excipients to be administered during
             dosing.

          -  Subject likely to not be available to complete all protocol-required study visits or
             procedures, and/or to comply with all required study procedures to the best of the
             subject and investigator's knowledge.

          -  History or evidence of any other clinically significant disorder, condition or disease
             (with the exception of those outlined above) or unacceptable physical findings, that,
             in the opinion of the investigator or Amgen physician, if consulted, would pose a risk
             to subject safety or interfere with the study evaluation procedures or completion.

          -  Subject previously has entered this study or previously received treatment with
             etelcalcetide.

          -  Anemia, which in the opinion of the investigator makes it not advisable to undergo
             sequential blood draws.

          -  History of unstable chronic heart failure within the last 1 year prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilinus</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary hyperparathyroidism (sHPT)</keyword>
  <keyword>Chronic kidney disease (CKD)</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) e product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities.There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

